<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Department of Medicine News and Stories

Patient Experience

Patient Care    Philanthropy    Clinical    Internal Medicine    Endowed Chair    Patient Experience

First Holder of Endowed Chair Seeks to Help ‘Define the Ideal Patient Experience’

Annie Moore, MD, MBA, is passionate about the clinical care experience of patients – and now she is the inaugural holder of a new endowed chair devoted to improving that experience. 

Author Mark Harden | Publish Date June 14, 2024
Full Story

Department of Medicine News & Stories

Department of Medicine In the News


Yes, the plague does still exist – here’s how to avoid it

news outletCPR
Publish DateJuly 10, 2024

In the Middle Ages, plague killed millions in Europe, claiming perhaps up to 200 million lives, half the continent’s population. But it's not just a thing of the past.

Full Story

Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy

news outletCGTV
Publish DateJuly 09, 2024

4D-710, 4D Molecular Therapeutics’ (4DMT) gene therapy candidate for treating cystic fibrosis, showcased CFTR transgene RNA and protein expression in all 10 participants treated at the higher and lower dose levels with follow-up up to 12 months in the phase 1/2 AEROW clinical trial (NCT05248230).

Full Story

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

news outletOncLive
Publish DateJuly 05, 2024

Although combination therapy with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib (MLN8237) resulted in marginal clinical benefit among patients with advanced solid tumors, correlative analyses indicated that apoptotic response and tumor immune cell infiltrate may affect clinical outcomes.

Full Story

Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi

news outletCGTV
Publish DateJuly 04, 2024

Lisocabtagene maraleucel (liso-cel) has demonstrated its ability to yield durable complete responses in patients with heavily pretreated mantle cell lymphoma and was FDA-approved for this indication in May 2024.

Full Story